1. Home
  2. FBRT vs CGEM Comparison

FBRT vs CGEM Comparison

Compare FBRT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin BSP Realty Trust Inc.

FBRT

Franklin BSP Realty Trust Inc.

HOLD

Current Price

$8.52

Market Cap

701.9M

Sector

Real Estate

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$13.81

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBRT
CGEM
Founded
2012
2016
Country
United States
United States
Employees
223
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
701.9M
904.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
FBRT
CGEM
Price
$8.52
$13.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$11.50
$30.13
AVG Volume (30 Days)
736.9K
881.8K
Earning Date
04-29-2026
05-11-2026
Dividend Yield
15.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.34
N/A
Revenue Next Year
$4.95
$5.20
P/E Ratio
$13.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.24
$5.68
52 Week High
$11.84
$16.74

Technical Indicators

Market Signals
Indicator
FBRT
CGEM
Relative Strength Index (RSI) 37.71 42.75
Support Level $8.38 $12.41
Resistance Level $9.26 $16.21
Average True Range (ATR) 0.21 0.94
MACD -0.06 -0.16
Stochastic Oscillator 6.83 11.57

Price Performance

Historical Comparison
FBRT
CGEM

About FBRT Franklin BSP Realty Trust Inc.

Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. The Company's operations are organized into two business units: (i) Commercial Real Estate Financing, and (ii) Agency Business. Its four reporting segments are as follows: The real estate debt business, The Agency Business, The commercial real estate conduit business, and The real estate owned business.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: